Compare MasterCard Inc (MA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MasterCard Inc trades at $561.9 (market cap $493.34B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: MasterCard Inc is far larger — about 3.7× Vertex Pharmaceuticals Incorporated's market cap, and MasterCard Inc pays a 0.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MA | VRTX | |
|---|---|---|
Market Cap | $493.34B | $132.79B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $529.65 |
52-Week Low | $471.55 | $376.62 |
Enterprise Value | $506.38B | $126.92B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.
The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
